Erratum: BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non-Small Cell Lung Cancer.

Remon J; Cascone T; Peters S

doi:10.1200/JCO-26-00221

← 뒤로

Erratum: BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non-Small Cell Lung Cancer.

0/5 보강

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 📖 저널 OA 34.8% 2022~2026 2026 Vol.44(8) p. 723

Remon J, Cascone T, Peters S

PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

↓ .bib ↓ .ris

APA Remon J, Cascone T, Peters S (2026). Erratum: BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non-Small Cell Lung Cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 44(8), 723. https://doi.org/10.1200/JCO-26-00221

MLA Remon J, et al.. "Erratum: BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non-Small Cell Lung Cancer.." Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 44, no. 8, 2026, pp. 723.

PMID 41650357 ↗

DOI 10.1200/JCO-26-00221

같은 제1저자의 인용 많은 논문 (2)

Unresectable stage III non-small-cell lung cancer: state of the art and challenges.
Nature reviews. Clinical oncology 2026
BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non-Small Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026